Searchable abstracts of presentations at key conferences in endocrinology

ea0065p350 | Reproductive Endocrinology and Biology | SFEBES2019

Gonadotrophin rise following the kisspeptin analogue (MVT-602) is increased in women with hypothalamic amenorrhoea compared to healthy women

Eng Pei Chia , Abbara Ali , Phylactou Maria , Clarke Sophie A , Yang Lisa , Mills Edouard , Modi Manish , Papadopoulou Deborah , Plumptre Isabella , Hunjan Tia , Purugganan Kate , Webber Lisa , Salim Rehan , Comninos Alexander N , Dhillo Waljit S

Introduction: Hypothalamic amenorrhoea (HA) is a condition characterised by reduced GnRH pulsatility and is a common cause of anovulatory subfertility. Kisspeptin is an endogenous neuropeptide that regulates hypothalamic GnRH function. Hypothalamic kisspeptin expression is reduced, and kisspeptin receptor expression is increased, in a rodent model of HA. The kisspeptin analogue MVT-602 has a 3-4-fold longer half-life than native kisspeptin-54 (t1/2 0.5 h). We invest...

ea0063gp15 | Calcium and Bone 1 | ECE2019

Recombinant human parathyroid hormone 1–84 for the treatment of adults with chronic hypoparathyroidism: Six-year safety and efficacy results of the RACE study

Bilezikian John P , Bone Henry , Clarke Bart L , Denham Douglas , Germak John , Lee Hak-Myung , Levine Michael A , Mannstadt Michael , Peacock Munro , Rothman Jeffrey G , Sherry Nicole , Shoback Dolores M , Vokes Tamara J , Warren Mark L , Watts Nelson B

Background: RACE is an open-label study that assessed the long-term safety and efficacy of recombinant human parathyroid hormone 1–84 (rhPTH[1–84]) for the treatment of hypoparathyroidism in adults (ClinicalTrials.gov identifier NCT01297309). Here, we present 6-year safety and efficacy data.Methods: Patients initially received 25 or 50 μg of rhPTH(1–84) subcutaneously, once daily, with stepwise dose adjustments of 25 μg (up or do...

ea0049gp47 | Bone & Calcium Homeostasis 2 | ECE2017

Recombinant human parathyroid hormone (rhPTH[1-84], parathyroid hormone rDNA) improves hypercalciuria in patients with hypoparathyroidism: 3-year analysis from RACE study

Clarke Bart L , Vokes Tamara J , Bilezikian John P , Bone Henry G , Denham Douglas S , Lee Hak-Myung , Levine Michael A , Mannstadt Michael , Peacock Munro , Rothman Jeffrey G , Shoback Dolores M , Warren Mark L , Watts Nelson B , Krasner Alan

Hypoparathyroidism (HPT) is characterised by hypocalcaemia and impaired renal phosphate excretion and calcium conservation. Oral calcium supplements and calcitriol can improve serum calcium levels but lack the physiologic effects of PTH on renal reabsorption of calcium. RACE is an ongoing open-label study evaluating the long-term safety of recombinant human parathyroid hormone 1-84 (rhPTH[1-84], parathyroid hormone rDNA) in adults with HPT (NCT01297309). In this interim analys...

ea0049gp131 | Female Reproduction | ECE2017

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial

Prague Julia , Roberts Rachel , Comninos Alexander , Clarke Sophie , Jayasena Channa , Nash Zachary , Doyle Chedie , Papadopoulou Deborah , Bloom Stephen , Mohideen Pharis , Panay Nicholas , Hunter Myra , Veldhuis Johannes , Webber Lorraine , Huson Les , Dhillo Waljit

Background: Hot flushes affect 70% of menopausal women, can be long-lasting, and often severely impact on physical, psychosocial, sexual, and overall wellbeing. Hormone replacement therapy is effective but not without risk. Neurokinin B is an important mediator of hot flushes in rodents and elevated hypothalamic expression occurs in menopausal women. Neurokinin B acts via the neurokinin 3 receptor. We therefore hypothesised that neurokinin 3 receptor antagonism could be a nove...

ea0044oc6.1 | Pregnancy and Reproductive Health | SFEBES2016

Two doses of kisspeptin improve oocyte maturation and implantation rates compared to a single kisspeptin injection during IVF treatment

Abbara Ali , Clarke Sophie , Islam Rumana , Prague Julia , Comninos Alexander , Narayanaswamy Shakunthala , Papadopolou Deborah , Roberts Rachel , Nesbitt Alexander , Izzi-Engbeaya Chioma , Vimalesvaran Sunitha , Ratnasabapathy Risheka , Salim Rehan , Lavery Stuart , Bloom Stephen , Trew Geoffrey , Dhillo Waljit

Background: In vitro fertilisation is an effective therapy for infertility, but can result in the potentially life-threatening complication, Ovarian Hyper-Stimulation Syndrome (OHSS). We have previously reported that a single injection of kisspeptin results in an LH surge of ~12–14 hrs duration, sufficient to safely induce oocyte maturation, but eliminate OHSS. However, the physiological LH surge in a normal menstrual cycle has a plateaux lasting 24–28 hrs. ...

ea0059oc4.2 | Clinical highlights | SFEBES2018

Kisspeptin- a novel clinical test of hypothalamic function in men with hypogonadotrophic hypogonadism

Chia Eng Pei , Abbara Sophie Clarke Ali , Phylactou Maria , Mills Edouard , Koteshwara Muralidhara , Chia Germaine , Yang Lisa , Pratibha Machenahalli C , Papadopoulou Deborah , Izzy-Engbeaya Chioma , Jayasena Channa , Comninos Alexander N , Dhillo Waljit S

Background: Hypogonadotrophic Hypogonadism (HH) is characterised by hypogonadism in the context of low gonadotrophin levels, frequently due to a defect in hypothalamic function e.g. Kallman’s syndrome. However, no direct test of hypothalamic function currently exists. Kisspeptin is a hypothalamic neuropeptide that stimulates endogenous GnRH release. Thus, we investigated whether kisspeptin could be used to interrogate hypothalamic function in men with HH.<p class="abs...

ea0059p124 | Neuroendocrinology and pituitary | SFEBES2018

A single bolus of the novel kisspeptin analogue, MVT-602, induces a prolonged LH surge compared to kisspeptin-54 during the follicular phase in healthy women

Clarke Sophie A , Abbara Ali , Chia Eng Pei , Phylactou Maria , Papadopoulou Deborah , Muralidhara Koteshwara , Mills Edouard , Jones Sophie , Pratibha Machenahalli C , Chia Germaine , Yang Lisa , Izzi-Engbeaya Chioma , Sykes Mark , Prague Julia K , Comninos Alexander N , Dhillo Waljit S

Background: Kisspeptin-54 (KP54) stimulates hypothalamic GnRH release. The kisspeptin analogue, MVT-602, has a longer half-life (t1/2108min) than KP54 (t1/228mins). MVT-602 potently stimulates gonadotrophin release in men. We sought to determine for the first time the effect of MVT-602 on gonadotrophin release in healthy women.Methods: A two-phase dose-finding study was carried out in 9 healthy women, 18–35 yrs with regular men...

ea0038ecp1.2 | (1) | SFEBES2015

Kisspeptin- A ‘key regulator’ of reproductive physiology, integrating limbic circuits with the regulation of reproductive hormones

Comninos Alexander , Anastasovska Jelena , Shah Amar , Wall Matthew , Jayasena Channa , Li Xiaofeng , Abbara Ali , Narayanaswamy Shaku , Nijher Gurjinder , Izzi-Engbeaya Chioma , Demetriou Lysia , Clarke Sophie , Ghatei Mohammad , Bell Jimmy , Matthews Paul , Bloom Stephen , O'Byrne Kevin , Dhillo Waljit

Kisspeptin is a recently identified reproductive hormone which serves as a crucial activator of the Hypothalamic–Pituitary–Gonadal (HPG) axis via stimulation of GnRH neurones. We have previously observed that a single kisspeptin injection increases LH pulsatility while twice daily kisspeptin injections can even advance the menstrual cycle. Furthermore, we have demonstrated that kisspeptin restores LH pulsatility in women with hypothalamic amenorrhoea and can potently...

ea0070oc6.5 | Hot Topics (including COVID-19 | ECE2020

TransCon PTH, a long-acting PTH, in patients with hypoparathyroidism: Results of the phase 2 PaTH forward trial

Sikjaer Tanja , Rejnmark Lars , Khan Aliya , Schwarz Peter , Vokes Tamara , Clarke Bart , Rubin Mishaela , Hofbauer Lorenz , Eriksen Erik , Palermo Andrea , Pagotto Uberto , Marcocci Claudio , Ahmed Intekhab , Mourya Sanchita , Markova Denka , Karpf David B

Background: Hypoparathyroidism (HP) is characterized by low serum calcium (sCa) and high serum phosphate (sP). Standard of care (SoC), active vitamin D and calcium, raises sCa and sP and increases burden of illness on HP patients by worsening hypercalciuria and the CaxP product. Parathyroid hormone (PTH)(1–84)(t1/2 ~2–3 hrs) is approved and can raise sCa and allow partial withdrawal of SoC, but does not sufficiently control urine calcium or symptoma...

ea0070oc9.2 | Reproductive and Developmental Endocrinology | ECE2020

Kisspeptin as a biomarker for pregnancy complications

Phylactou Maria , Abbara Ali , Chia Eng Pei , Al-Memar Maya , Comninos Alexander , Nadir Rans , Izzi-Engbeaya Chioma , Clarke Sophie , Mills Edouard , Sykes Mark , Pacuszka Ewa , Yang Lisa , Fourie Hanine , Bech Paul , Kelsey Tom , Bourne Tom , Dhillo Waljit

Background: Placentation (invasion of the placenta into the maternal endometrium of pregnancy known as the decidua) is hypothesised to be critical for healthy placental function and is abnormal in two thirds of miscarriage. Kisspeptin has emerged as a putative regulator of physiological placentation; it is highly expressed in placental syncitio-trophoblasts, whereas its receptor is expressed in both syncitio- and cyto-trophoblasts, such that kisspeptin is hypothesized to play ...